Bristol-Myers Squibb Company ( (BMY) ) has released its Q3 earnings. Here is a breakdown of the information Bristol-Myers Squibb Company presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bristol Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, primarily in the fields of oncology, immunology, and cardiovascular disease.
In the third quarter of 2025, Bristol Myers Squibb reported a 3% increase in total revenues, reaching $12.2 billion, driven by strong performance in its Growth Portfolio. The company also raised its full-year revenue guidance to a range of $47.5 billion to $48.0 billion, reflecting continued momentum and strategic advancements.
Key highlights include an 18% increase in Growth Portfolio revenues, primarily fueled by products like Opdivo, Reblozyl, and Breyanzi. However, the Legacy Portfolio saw a 12% decline due to generic competition. The company reported GAAP EPS of $1.08, an 81% increase from the previous year, while non-GAAP EPS was $1.63, impacted by IPRD charges and licensing income.
Bristol Myers Squibb continues to advance its pipeline with significant milestones, including positive trial results for Sotyktu and a strategic acquisition of Orbital Therapeutics to enhance its RNA technology platform. These efforts align with the company’s focus on delivering transformational medicines and expanding its therapeutic applications.
Looking ahead, Bristol Myers Squibb remains committed to accelerating innovation and advancing its pipeline, with a focus on delivering more transformative medicines to patients. The company anticipates continued growth and strategic development in the coming quarters.